CVS Health Corp

CVS: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$67.00KrvwpnfWyfrflnkk

CVS Earnings: Surging Medical Utilization Cuts Into 2024 Outlook Again

Narrow-moat CVS Health delivered weak second-quarter results, primarily on deflated profits in Medicare Advantage, where spiking medical utilization and mispriced plans caused profits to decline substantially. Because this weakness may continue, management cut its 2024 guidance for the second time this year. However, changing our near-term estimates a bit does not materially affect our $93 fair value estimate, and shares remain cheap relative to the firm's longer-term prospects, in our opinion.

Sponsor Center